Delta Global Management LP Purchases New Stake in Zoetis Inc. $ZTS

Delta Global Management LP acquired a new position in Zoetis Inc. (NYSE:ZTS) in the 1st quarter, HoldingsChannel.com reports. The firm acquired 19,059 shares of the company’s stock, valued at approximately $2,253,000.

Other institutional investors have also recently bought and sold shares of the company. Prosperity Bancshares Inc acquired a new position in shares of Zoetis in the 4th quarter valued at about $25,000. Cassaday & Co Wealth Management LLC purchased a new stake in shares of Zoetis in the first quarter worth approximately $28,000. Lodestone Wealth Management LLC acquired a new stake in shares of Zoetis during the fourth quarter worth approximately $30,000. Elyxium Wealth LLC acquired a new stake in shares of Zoetis during the fourth quarter worth approximately $32,000. Finally, Root Financial Partners LLC grew its position in Zoetis by 66.5% during the first quarter. Root Financial Partners LLC now owns 258 shares of the company’s stock valued at $30,000 after purchasing an additional 103 shares in the last quarter. 92.80% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Zoetis

In other news, Director Paul Bisaro acquired 2,000 shares of the stock in a transaction dated Wednesday, May 13th. The shares were acquired at an average cost of $75.88 per share, for a total transaction of $151,760.00. Following the completion of the transaction, the director owned 27,862 shares in the company, valued at approximately $2,114,168.56. This trade represents a 7.73% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, Director Frank A. Damelio purchased 6,650 shares of the stock in a transaction on Wednesday, May 13th. The stock was acquired at an average cost of $75.39 per share, for a total transaction of $501,343.50. Following the acquisition, the director directly owned 21,458 shares in the company, valued at approximately $1,617,718.62. This trade represents a 44.91% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Insiders bought 11,650 shares of company stock worth $886,384 over the last ninety days. Company insiders own 0.22% of the company’s stock.

Zoetis Trading Up 1.0%

NYSE:ZTS opened at $75.32 on Friday. The company has a market capitalization of $31.58 billion, a P/E ratio of 12.49, a P/E/G ratio of 1.18 and a beta of 0.75. The stock’s 50 day moving average price is $77.29 and its 200 day moving average price is $104.25. The company has a debt-to-equity ratio of 2.80, a quick ratio of 1.91 and a current ratio of 3.15. Zoetis Inc. has a 52 week low of $71.47 and a 52 week high of $160.48.

Zoetis (NYSE:ZTS) last posted its earnings results on Thursday, May 7th. The company reported $1.53 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.60 by ($0.07). The business had revenue of $2.26 billion during the quarter, compared to analyst estimates of $2.30 billion. Zoetis had a net margin of 27.80% and a return on equity of 66.85%. Zoetis’s revenue was up 2.9% compared to the same quarter last year. During the same quarter last year, the firm earned $1.48 earnings per share. Zoetis has set its FY 2026 guidance at 6.850-7.000 EPS. On average, research analysts forecast that Zoetis Inc. will post 6.87 EPS for the current fiscal year.

Zoetis Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 1st. Investors of record on Monday, July 20th will be paid a $0.53 dividend. This represents a $2.12 annualized dividend and a dividend yield of 2.8%. The ex-dividend date of this dividend is Monday, July 20th. Zoetis’s payout ratio is presently 35.16%.

Wall Street Analysts Forecast Growth

ZTS has been the topic of several research reports. TD Cowen dropped their price objective on shares of Zoetis from $150.00 to $104.00 and set a “buy” rating on the stock in a research note on Tuesday, June 30th. Morgan Stanley decreased their target price on shares of Zoetis from $115.00 to $99.00 and set an “overweight” rating for the company in a research note on Wednesday. JPMorgan Chase & Co. dropped their price target on shares of Zoetis from $190.00 to $130.00 and set an “overweight” rating on the stock in a research note on Friday, May 8th. Argus reiterated a “hold” rating on shares of Zoetis in a report on Wednesday, May 27th. Finally, Barclays cut their price objective on Zoetis from $136.00 to $85.00 and set an “equal weight” rating for the company in a report on Wednesday, July 1st. Eight investment analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Zoetis currently has a consensus rating of “Hold” and a consensus target price of $119.50.

Trending Headlines about Zoetis

Here are the key news stories impacting Zoetis this week:

• Negative Sentiment: Several firms announced or promoted securities-fraud litigation against Zoetis, which can weigh on sentiment by raising legal, financial, and reputational risk for the company. Zoetis Inc. (ZTS) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
• Negative Sentiment: The class-action deadline reminders may keep the controversy in the spotlight and encourage more shareholder claims, adding overhang to the stock. ZOETIS CLASS ACTION DEADLINE MONDAY JULY 27th
• Neutral Sentiment: One Seeking Alpha commentary argues Zoetis sentiment remains strong and fundamentals are improving, offering a more constructive longer-term view. Zoetis: Sentiment Keeps Winning As Fundamentals Improve

About Zoetis

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.